Q3 Interim Report 2021

Audiocast at 10:00 am CET November 18, 2021

SCANDION ONCOLOGY

Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.

This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.



Agenda

• Highlights from Q3, 2021

O Clinical Pipeline

Financial Update Q3, 2021

Outlook for 2021 – 2022

Event Calendar

Investment Highlights



Close to 10 million people are dying from cancer every year 90% of cancer deaths are due to drug resistant cancer cells

The overall estimation of cancer patients who will respond to immunooncology agents is 13%

Highlights from Q3, 2021

- August 25 US Patent and Trademark Office (USPTO) will grant the company's patent directed to the use of SCO-101
- August 27 Approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study
- **September 2** Scandion Oncology and Alligator Bioscience announced the conclusion of their collaboration with a very positive outcome
- September 6Approval of the amendment of part 2 of CORIST Phase II study by the
Danish Medicines Agency and the Ethics Committee
- September 7 Scandion Oncology's Clinical Advisory Board strengthened by three additional members
- **September 8** Scandion Oncology provided novel information on its lead candidate drug SCO-101 and a focused clinical strategy with a clear path to registration at its Capital Markets Day

November 8 Read-out from PANTAX Phase Ib study postponed





Scandion Oncology's Clinical Advisory Board

- Strengthened by three additional members



Richard L. Schilsky MD, FACP, FSCT, FASCO

Former Executive Vice President and Chief Medical Officer of American Society of Clinical Oncology (ASCO) and past President of ASCO (2008-2009). Former Board member of Conquer Cancer, the ASCO Foundation



Josep Tabernero MD, PhD

Member of the Executive Board of the European Society for Medical Oncology (ESMO) and past ESMO President (2018 – 2019). Appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and ESMO-GI/WCGIC meetings



Eric Van Cutsem MD, PhD

President of the Belgian Foundation against Cancer. He co-founded ESMO GI/World Congress on Gastrointestinal Cancer, and is Chair of the meeting in Barcelona, Spain. He serves/served on the board or key committee of ESMO, ASCO, EORTC, ENET, ECCO, ESDO, and many others



Thomas Seufferlein

President of the German Cancer Society (DKG) and chairman of the committee for cancer prevention of the German Cancer Aid (DKH). Editor in Chief of the German Journal of Gastroenterology



- Focused clinical strategy with a clear path to market for SCO-101
- Positioning of market opportunities for SCO-101
- Novel insights on unique mode-of-action of SCO-101
- Recording can be found on Company homepage



PANTAX Phase Ib Study Read-out Postponed

- Recruitment rate lower than anticipated
- 1. More challenging to recruit patients than expected
- 2. Clinical sites in Denmark opened slower than planned
- 3. To internationalize the study, it expanded to Germany where the German Competent Authority required a staggered design
- Read-out now expected in Q2-Q3, 2022

"Disregarding the postponement, the study is performing as well as we could have hoped for"





Clinical Pipeline

Developing first-in-class medicines for personalized therapy targeting cancer drug resistance

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer (RAS wt)				
ΡΑΝΤΑΧ	SCO-101	Pancreatic cancer				
BIOMARKER DEVELOPMENT	SCO-101	Colorectal and Pancreatic cancer				

Clinical Highlights Q3, 2021

- **PANTAX:** Approval to initiate clinical trials in Germany, on **August 27, 2021**
- **CORIST:** Approval for initiating part 2 of the CORIST Phase II study, on **September 6, 2021**
- **PANTAX:** Data read-out from PANTAX Ib study postponed, on **November 8, 2021**

Upcoming Key Events in 2021-2022

- CORIST: Data read-out from CORIST part 2 is planned for Q2-Q3, 2022
- **PANTAX:** Data read-out from PANTAX Phase Ib is planned for **Q2-Q3, 2022**



Financial Update Q3, 2021



Financial Overview

- Net result and cost, overall in line with expectations
- Continued strengthening of the organization, according to plan
- Cost of the ongoing clinical studies CORIST and PANTAX, will further increase as the studies progress


Financial summary	Q3		Ytd		Full year
DKK '000	2021	2020	2021	2020	2020
Net sales Other income	0 98	0 0	0 209	0 427	0 1,003
Staff cost Other expenses	-7,104 -8,300	-2,123 -2,788	-16,467 -24,260	-5,603 -8,533	-9,396 -14,495
Financial items Tax	-349 346	-46 1,066	-1,594 5,500	-394 3,032	2,235 4,384
Net result	-15,309	-3,891	-36,612	-11,071	-16,269
Earnings per share (DKK)	-0.48	-0.20	-1.14	-0.58	-0.83
Cash position	117,360	7,505	117,360	7,505	5,814



Cash Position



Operating Expenses 2020 - Q3 2021



Progression of clinical studies

Increase in operating expenses and cash spend will continue going forward driven by the planned progression of the clinical studies CORIST and PANTAX



Expected Significant Events 2021 - 2022




Financing secured until at least after 2022

Q3 Interim Report November 18, 2021



Event Calendar





Why Invest in Scandion Oncology

We are first movers in cancer drug resistance

• We are first-in-class, targeting a gigantic market

High medical need and yet also an established market

- 10M cancer-related deaths annually
- SCO-101 has platform potential

De-risked clinical asset

- Near proof-of-concept and valueinflection
- Pivotal trial within reach in 2023

Highly focused pipeline and clinical development

- Focused early-stage pipeline for value creation
- Plethora of opportunities to broaden into other cancer indications

Run by seasoned leadership team

- Leadership team with a clear track record
- Best in class CAB
- Strong and well-connected BoD

Multiple value inflection points over the next few years

- PoC mCRC Phase II in Q2-Q3, 2022
- PDAC Phase Ib study read-out in Q2-Q3, 2022



Investor Relations: Bo Rode Hansen, President & CEO Email: ir@scandiononcology.com Phone: +45 38 10 20 17

Sign up to Scandion news on our website:

www.scandiononcology.com

Q&A

